Faruqi and Faruqui, LLP Logo
Share this page

Obagi Medical Products, Inc. (OMPI)

(NASDAQ: OMPI)

Summary

Faruqi & Faruqi, LLP is Seeking More Cash for the Shareholders of Obagi Medical Products, Inc. (OMPI)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Obagi Medical Products, Inc. (“Obagi” or the “Company”) (NASDAQ: OMPI) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) in an all-cash deal valued at approximately $360 million.  Under the terms of the proposed transaction, Obagi’s stockholders will receive $19.75 for each share of Obagi common stock they own. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.

The investigation focuses on whether Obagi’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Obagi’s shareholders. 

If you own common stock in Obagi and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Obagi Medical Products, Inc. (OMPI)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.